Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2023 Annual Meeting
Flatiron Health today announced that the company and its collaborators will present a total of 12 abstracts accepted for poster discussion, presentation, and online publication at this year's American Society of Clinical Oncology (ASCO) Annual meeting, to be held in Chicago this June.
"As demonstrated by our presence at ASCO this year, Flatiron is continuing to scale our ability to connect powerful data and novel technology to better design trials for diversity, accelerate clinical research timelines, reduce burden across teams and complete trials with more confidence," shares Flatiron Health Chief Medical Officer Javier Jimenez. "Aligned with this year's theme, Flatiron's intimate knowledge of the oncology healthcare ecosystem and multi-faceted and deep understanding of EHR data positions us to continue developing technology and driving research to close the gap between care and research."
Research highlights include:
Learn more about our abstracts and events by visiting our website.
Follow Flatiron Health on Twitter and LinkedIn for more updates from #ASCO23 and visit us in person at Booth #23127.
Poster Discussions and Presentations
Mediators of racial/ethnic inequities in clinical trial participation among US patients with cancer, 2011-2022.
Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types
Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting.
Technology-enabled clinical trials: Intentional capture of source data (IDC) in the electronic-health record (EHR) and direct transfer to trial database (electronic data capture [EDC]) in a phase II multicenter trial.
Trial eligibility criteria (EC) and diversity among patients with advanced non small cell lung cancer (advNSCLC).
Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC).
Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets.
Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice.
Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns.
Evaluating Generalizability of Practice-Changing Randomized Clinical Trials in Non-Small Cell Lung Cancer using Machine Learning-Based In-Silico Trials.
Clinical pathways innovation: A lesson on the value of clinician based feedback and collaboration with Flatiron Health
About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005170/en/